Christopher Venner

Contact Overview Publications

Contact

Faculty of Medicine & Dentistry - Medicine Dept

Email: cvenner@ualberta.ca
Phone: (780) 432-8757
Address: Clinical Sciences Building
11304 83 Ave NW

Edmonton AB

T6G 2G3

Overview

Area of Study / Keywords

Myeloma Database Canada Real world evidence

About

Dr. Christopher Venner is currently appointed as Assistant Professor in the Department of Medicine in the Faculty of Medicine & Dentistry.

Research

Myeloma, Waldenstroms macroglobulinemia, Amyloidosis, Drug Development, Stem Cell Transplantation, Correlative Biology, Genomics

Featured Publications

Frequency, Timing, and Predictors of Palliative Care Consultation in Patients with Advanced Cancer at a Tertiary Cancer Center: Secondary Analysis of Routinely Collected Health Data

Watanabe S.M., Faily V., Mawani A., Huot A., Tarumi Y., Potapov A., Fassbender K., Fairchild A., Joy A.A., King K.M., Roa W., Venner C.P., Baracos V.E.

The Oncologist. 2020 August; 25 (8):722-728 10.1634/theoncologist.2019-0384

Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium

Bergstrom D.J., Kotb R., Louzada M.L., Sutherland H.J., Tavoularis S., Venner C.P., Côté J., LeBlanc R., Reiman A., Sebag M., Song K.W., Colasurdo G., Del Col A., McMullen D., Hay A.E., Laferriere N.M.B., Robertson McCurdy A.B., Roy J., Stakiw J.L., Trudel S.M., White D.J., Loveys F.W., Randell E., Rizkalla K.S.

Clinical Lymphoma Myeloma & Leukemia. 2020 July; 20 (7):e352-e367 10.1016/j.clml.2020.01.017

SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY

European Hematology Association Annual Congress. 2020 June;

A PHASE 2 STUDY OF BELANTAMAB MAFODOTIN (GSK2857916) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FOR PART 1 DOSE FINDING

European Hematology Association Annual Congress. 2020 June;

CARFILZOMIB, DEXAMETHASONE (KD) AND DARATUMUMAB VERSUS KD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE CANDOR STUDY BY NUMBER OF PRIOR LINES OF THERAPY AND PRIOR THERAPIES

European Hematology Association Annual Congress. 2020 June;

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM)

American Society of Clinical Oncology. 2020 May;

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)

American Society of Clinical Oncology. 2020 May;

Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

Royal V., Leung N., Troyanov S., Nasr S.H., Écotière L., LeBlanc R., Adam B.A., Angioi A., Alexander M.P., Asunis A.M., Barreca A., Bianco P., Cohen C., Drosou M.E., Fatima H., Fenoglio R., Gougeon F., Goujon J.M., Herrera G.A., Knebelmann B., Lepori N., Maletta F., Manso R., Motwani S.S., Pani A., Rabant M., Rennke H.G., Rocatello D., Rosenblum F., Sanders P.W., Santos A., Soto K., Sis B., Touchard G., Venner C.P., Bridoux F.

BLOOD. 2020 May; 135 (21):1833-1846 10.1182/blood.2019003807